J&J's TECNIS PureSee IOL Data Bolsters EDOF Lens Market Position
Event summary
- Johnson & Johnson presented data at the 2026 ASCRS Annual Meeting supporting the performance of its TECNIS PureSee intraocular lens (IOL).
- Two studies, one post-market observation (293 patients across 19 sites) and one U.S. clinical trial (200 patients across nine sites), demonstrated improved visual outcomes and patient satisfaction.
- The post-market study showed 96% spectacle independence for distance, 95% for intermediate, and 61% for near vision.
- Clinical trial data showed improved intermediate vision compared to monofocal IOLs, with comparable distance visual acuity.
The big picture
The TECNIS PureSee IOL represents Johnson & Johnson’s continued investment in the premium cataract surgery market, a segment driven by aging populations and a desire for reduced reliance on corrective eyewear. The data presented reinforces J&J’s position in the EDOF IOL space, but the market remains competitive, with other players vying for surgeon preference and patient adoption. Success hinges on demonstrating a clear clinical advantage and securing favorable reimbursement.
What we're watching
- Market Adoption
- The pace at which surgeons adopt TECNIS PureSee will determine its impact on J&J’s ophthalmology revenue, especially given the competitive landscape of EDOF IOLs.
- Reimbursement
- Whether payers will favorably reimburse TECNIS PureSee based on the presented clinical data will be crucial for broader market penetration.
- Competitive Response
- Competitors will likely respond with their own EDOF lens innovations, potentially intensifying the competition for market share in the premium cataract surgery segment.
Related topics